Business context and reporting period
The supplied filing is Virios Therapeutics, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2023, not a filing under the name Dogwood Therapeutics, Inc. Virios is a pre-revenue, development-stage biotechnology company developing IMC-1, a fixed-dose combination of famciclovir and celecoxib, initially for fibromyalgia.
Financial performance and liquidity
| Metric | Q1 2023 | Q1 2022 or prior period |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $497,714 | $2,769,102 |
| General and administrative expense | $1,059,573 | $1,192,112 |
| Total operating expenses | $1,557,287 | $3,961,214 |
| Net loss | $1,516,864 | $3,960,308 |
| Net cash used in operating activities | $1,698,450 | $2,656,017 |
| Cash | $5,332,542 at March 31, 2023 | $7,030,992 at December 31, 2022 |
| Total liabilities | $549,290 | $1,043,262 at December 31, 2022 |
There was no debt outstanding and no financing cash flow in the quarter. Current assets were $6.52 million, stockholders’ equity was $5.97 million, and accumulated deficit was $57.69 million. The company reported no product revenue; profit margins therefore are not meaningful.
Material changes and operating developments
- R&D expense fell by about $2.3 million year over year, mainly because clinical-trial spending declined by $2.2 million; G&A decreased by about $0.1 million.
- Cash declined by about $1.70 million from year-end 2022. Management estimated cash would fund operating expenses and obligations for at least 12 months from the financial-statement issuance date, but said additional capital would be needed for further clinical development.
- Q1 2023 weighted-average shares were 18.33 million versus 8.33 million a year earlier. The company’s September 2022 public offering issued 10 million shares and raised $5.0 million gross, approximately $4.49 million net.
Outlook, risks, and contingencies
- The FORTRESS Phase 2b study did not meet its prespecified primary efficacy endpoint (p=0.302). The company highlighted a subgroup of community-based patients without prior fibromyalgia-trial participation that showed statistically significant improvement, and plans to focus future development on this population.
- After a March 2023 meeting, the FDA gave initial feedback that the proposed Phase 3 program was acceptable, pending review of final chronic toxicology results submitted in May 2023. The proposed program includes two controlled studies, a long-term safety trial, and a pharmacokinetic/food-effect study. These are plans, not final authorization.
- Management said no major new R&D activities were planned for the next 12 months beyond specified carryover work, regulatory consulting, the Long-COVID investigator-sponsored study, and preparation for the proposed pharmacokinetic/food-effect study. Long-COVID study data were expected in June 2023.
- The company expects continuing losses and must obtain further financing for Phase 3 and other development. Financing may be unavailable or dilutive; failure to secure it could delay development. Management’s 12-month cash estimate does not remove this longer-term funding risk.
- Nasdaq granted an extension through October 30, 2023 to regain compliance with the $1.00 minimum bid-price rule. The company also disclosed ordinary-course litigation exposure but no material pending litigation, and a related-party consulting arrangement with the CMO’s firm.
Important facts for investors to verify
- Confirm the issuer identity: the filing text names Virios Therapeutics, Inc., whereas the request identifies Dogwood Therapeutics, Inc.
- Review final FDA feedback on the chronic toxicology submission and whether the proposed Phase 3 design and timing proceed as described.
- Assess the full FORTRESS results and the evidence supporting the highlighted subgroup, given the failed primary endpoint.
- Check actual cash burn, financing needs and available funding after the stated 12-month runway estimate.
- Verify Nasdaq bid-price compliance status and any actions affecting the share count or potential dilution.